Huiyi Huiying

Huiyi Huiying operates in the healthcare technology sector, specializing in artificial intelligence solutions that enhance medical diagnostics and healthcare delivery through advanced imaging tools. Founded in 2015 in Beijing, China, Huiyi Huiying focuses on integrating AI technologies in the healthcare field to optimize diagnostic processes. The company operates independently without known subsidiaries or parent companies. Its latest funding round, a Series B, raised USD 15.

00 mn led by Delta Capital. Total funds raised by the company amount to USD 15. 00 mn, highlighting its growth in the healthcare technology arena. HY Medical specializes in leveraging artificial intelligence to enhance tiered diagnosis and personalized healthcare solutions.

Its core offerings include the Smart Imaging Cloud Platform and integrated digital imaging solutions, which facilitate the efficient management and analysis of medical imaging data. These products aim to address challenges in medical diagnostics by providing advanced AI-assisted diagnostic tools that improve accuracy and speed in clinical settings. The company serves a range of clients, including individual hospitals and regional health committees, primarily within China, while also expanding its reach into international markets across Asia and Europe. By integrating big data and AI applications, HY Medical enhances healthcare delivery and contributes to the advancement of precision medicine.

The revenue generation model for HY Medical is primarily structured around subscription-based services and direct partnerships with healthcare providers. Clients engage with the company through various channels, such as B2B agreements, where healthcare institutions subscribe to the Smart Imaging Cloud Platform for ongoing access to AI-driven diagnostic tools. This model allows hospitals to integrate the company's solutions into their existing operations seamlessly. Specific pricing structures for these services are tailored to meet the varying needs of clients, ensuring that they can access advanced imaging solutions while managing costs effectively.

The flagship products not only provide essential diagnostic assistance but also support the broader goal of enhancing healthcare outcomes through data-driven insights. Looking ahead, Huiyi Huiying aims to launch new AI-driven diagnostic products by mid-2022 to expand its suite of healthcare solutions. Additionally, the company is targeting expansion into international markets, specifically aiming to establish a stronger presence in Southeast Asia and Europe by the end of 2023. The recent funding of USD 15.

00 mn will support these initiatives, particularly in product development and market entry strategies.